953410-86-1

Basic information

• Product Name: 1H-Indazole, 5-bromo-7-iodo-
• Synonyms: 1H-Indazole, 5-bromo-7-iodo-;5-Bromo-7-iodo-1H-indazole
• CAS NO: 953410-86-1
• Molecular Formula: C₇H₄BrIN₂
• Molecular Weight: 322.92853
• Mol File: 953410-86-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 410.4±30.0 °C(Predicted)
• Appearance: /
• Density: 2.421±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 10.78±0.40(Predicted)
• CAS DataBase Reference: 1H-Indazole, 5-bromo-7-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole, 5-bromo-7-iodo-(953410-86-1)
• EPA Substance Registry System: 1H-Indazole, 5-bromo-7-iodo-(953410-86-1)

Safety Data

• Hazardous Substances Data: 953410-86-1(Hazardous Substances Data)

Usage

General Description

1H-Indazole, 5-bromo-7-iodo- is a chemical compound with the molecular formula C7H4BrIN2. It is a derivative of indazole, a heterocyclic aromatic organic compound. 1H-Indazole, 5-bromo-7-iodo- is a yellow solid at room temperature and is sparingly soluble in water. 1H-Indazole, 5-bromo-7-iodo- is commonly used as a building block in organic synthesis and is also known for its potential pharmacological activities. It has been studied for its use in the development of pharmaceutical drugs and as a substrate for various chemical reactions in the laboratory. Additionally, it has been investigated for its potential as a catalyst in organic reactions.

Upstream product

• 922170-67-0 4-bromo-2-iodo-6-methylaniline 
• 583-75-5 4-Bromo-2-methylaniline 

Relevant articles and documents

Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay

Inappropriate activation of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythematosus (SLE). Herein, the development of a TLR8 antagonist competition assay and its application for hit generation of dual TLR7

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.